CHAI is pleased to share a customizable guide to assist healthcare workers with prescribing and dispensing second-line (2L) DRV/r (400/50mg).
This prescribing memo has been developed to assist healthcare workers with prescribing DRV/r for use after dolutegravir (DTG) failure or intolerability in patients who have not previously failed a PI (or in patients confirmed to have no DRV resistance-associated mutations following prior PI use) or those interested in switching to DRV/r given improved tolerability and efficacy over other PIs.
This can be a standalone guide or incorporated into other training materials. This resources is being shared in PPT format so that it can easily be customized to fit an individual country’s local context.
Comments